Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Add as a preferred source on Google
Dublin, April 13, 2018 -- The "Acute Decompensated Heart Failure Forecast and Market Analysis to 2034" report has been added to ResearchAndMarkets.com's offering.
Acute decompensated heart failure (ADHF) is defined as the sudden worsening of heart failure symptoms (mainly edema, dyspnea, and fatigue), which results in severe respiratory distress. ADHF is categorized into hemodynamic stages based on the degree of perfusion and pulmonary capillary wedge pressure. Despite improvements in treatment, ADHF is a burdensome disease associated with high hospitalization and mortality rates in the elderly population.
Recent events and opinion
- ADHF treatment is focused on hemodynamic stabilization and alleviation of symptoms.
- The author estimates that in 2016, there were 1.2 million diagnosed incident cases of ADHF in the US, Japan, and five major EU markets.
- Natrecor and Simdax have had limited success in the highly genericized ADHF market.
- Discontinuations of ularitide and Reasanz have left the ADHF pipeline bare.
Key Topics Covered:
1 Treatment: Acute Decompensated Heart Failure (Published on 19 January 2018)
- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Current Treatment Options
- Prescribing Trends
2 Epidemiology: Acute Decompensated Heart Failure (Published on 18 January 2018)
- Executive Summary
- Disease Background
- Sources And Methodology
- Forecast
- Epidemiologist Insight
- Strengths And Limitations
- Bibliography
- Appendix: Additional Sources
3 Marketed Drugs: Acute Decompensated Heart Failure (ADHF) (Published on 15 February 2018)
- Executive Summary
- Product Overview
- Diuretics
- Vasodilators
- Inotropic Agents
- Other Drug Classes
- Product Profile: NATRECOR
- Product Profile: SIMDAX
4 Pipeline: Acute Decompensated Heart Failure (ADHF) (Published on 15 February 2018)
- Executive Summary
- Clinical Pipeline Overview
- Recently Discontinued Drugs
- Product Profile (Late Stage): BMS-986231
For more information about this report visit https://www.researchandmarkets.com/research/gn65vq/world_acute?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiology
